ClinicalTrials.gg
CompletedNCT04259281Updated Jan 9, 2026

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

A Phase 1/2 interventional study of GTX-102 in Angelman Syndrome, sponsored by Ultragenyx Pharmaceutical Inc. Completed at 25 sites in 8 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Ultragenyx Pharmaceutical Inc · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.

Enrollment
11th of 24
74 · median 73
Started
2020
with 1 other
Phase 1/2
3 of 33
1 open now
Registered
18th of 33
by date
Lead sponsor
4 of 33
Ultragenyx Pharmaceutical Inc

Among the 33 studies in Angelman Syndrome with a site in United States, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 1/2, and was the 18th registered.

Angelman Syndrome

52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.

Browse Angelman Syndrome studies →

Open to participants now

6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Angelman Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (AS).

Read the detailed description

This is a Phase 1/2, open-label, multiple-dose, study to evaluate the safety, tolerability, and plasma and CSF concentrations of GTX-102 in pediatric participants with AS.

The study includes a Loading phase followed by a Maintenance phase. Participants may continue on GTX-102 during the Maintenance phase of the study until GTX-102 is commercially available, intolerable toxicity occurs, the parent/legal guardian withdraws consent, the participant enrolls in another experimental study, or this study is terminated.

This study was previously posted by GeneTX Biotherapeutics, LLC and was transferred to Ultragenyx in July 2022.

03

Conditions studied

  • Angelman Syndrome

Browse trials for

04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed from parent(s) or legal guardian(s)
  • Documented genetic confirmation of full maternal UBE3A gene deletion causing AS in the region of 15q11.2-q13 including class I, II or III
  • Stable seizure control (defined as clinically stable with no changes in antiepileptic medications over the prior 1 month before the screening visit, other than weight associated dose adjustments)
  • Able to ambulate independently, or with an assistive device (note, a child whose primary means of mobility is by wheelchair is excluded from the study)
  • count, / international normalized ratio, and partial thromboplastin time within 1.2 x the normal limits
  • Normal renal function with serum creatinine and spot urine protein ≤ 1.4 x the (ULN)
  • Normal hepatic function with total , , alanine aminotransferase, and alkaline phosphatase ≤ 1.4 x ULN. Exception: levels ≤ 2 × ULN are acceptable if due to anti-epileptic drugs (AEDs) or Gilbert syndrome
  • Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, study restrictions, and all study procedures, including LP procedure
  • Able to tolerate the anesthetic regimen, if required for LP procedure
  • A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Female of non- (ie, pre-menarche), Female of childbearing potential who agrees to remain abstinent (refrain from heterosexual intercourse) or use acceptable methods during the treatment period and for at least 3 months after the final dose of GTX-102
  • A male patient is eligible to participate if he agrees to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for at least 3 months after the final dose of GTX-102

Exclusion criteria

Exclusion Criteria:

  • Any change in medications (excluding AEDs) or diet/supplements intended to treat symptoms of AS (eg, sleeping aids, supplements, dietary change including ketogenic or low-glycemic index diet, other) over the prior 1 month before screening
  • Any bleeding or disorder
  • Any cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurological, malignant, metabolic, psychiatric, or other condition that, in the judgment of the Investigator, will pose a safety risk, make the patient unsuitable for participation in, and/or unable to complete the study procedures
  • Any laboratory abnormality, that, in the Investigator's opinion, could adversely affect the safety of the patient, make it unlikely that the course of treatment or follow up would be completed, or impair the assessment of study result
  • Known positive for virus, virus, or
  • Any active infection
  • Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
  • Drugs that increase the risk of bleeding (eg, heparin, low molecular weight heparin, platelet inhibitors)
  • Any prior use of gene therapy
  • Use of any drugs in the past 6 months or within 5 half-lives, whichever period is greater (with the exception of prior GTX 102)
  • Known to any oligonucleotide, as demonstrated by an immune mediated reaction (eg, pneumonitis, hepatitis, nephritis, neuritis, or other system inflammation), or a systemic allergic reaction such as signs and symptoms of anaphylaxis, urticaria, clinically significant rash
  • Patient is pregnant or lactating
  • Any medical condition that would require intubation for the anesthesia procedure
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    GTX-102 Cohort 1

    3.3 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to \<17 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort 2

    10 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to \<17 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort 3

    20 mg starting dose followed by intra-patient dose escalation up to 55 mg and then a maintenance phase (in U.S participants 4 to \<17 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort 4

    3.3 mg starting dose followed by slow intra-patient dose escalation up to 5 mg and then a maintenance phase (in Ex-U.S participants 4 to \<8 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort 5

    5 mg starting dose followed by slow intra-patient dose escalation up to 7.5 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort 6

    7.5 mg starting dose followed by slow intra-patient dose escalation up to 10 mg and then a maintenance phase (in Ex-U.S participants 4 to \<8 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort 7

    10 mg starting dose followed by slow intra-patient dose escalation up to 12 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort US

    2 mg for 4 monthly doses followed by a quarterly maintenance regimen

    Drug: GTX-102

  • Experimental
    GTX-102 Expanded Enrollment Cohort A

    Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants 4 to \<8 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Expanded Enrollment Cohort B

    Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Expanded Enrollment Cohort C

    Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants 4 to \<8 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Expanded Enrollment Cohort D

    Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants ≥ 8 to 17 years of age)

    Drug: GTX-102

  • Experimental
    GTX-102 Cohort E

    Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in participants that transition from GTX-102 US Cohort only)

    Drug: GTX-102

Interventions

  • antisense oligonucleotide

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs), Serious AEs (SAEs), Adverse Events of Special Interest (AESIs), AEs Leading to Discontinuation and Severity of AEs

    Time frame: Up to Day 337

Secondary outcomes

  1. Pharmacokinetics of GTX-102 over time

    Maximum drug concentration (Cmax)

    Time frame: Up to Day 337

07

Study locations

25 sites
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Rare Disease Research
    Atlanta, Georgia 30318, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • The Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • Queensland Children's Hospital
    South Brisbane, QLD 4101, Australia
  • MAGIC Clinic Ltd
    Calgary, Alberta T2E 7Z4, Canada
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H3V4, Canada
  • Children's Hospital of Western Ontario
    London, Ontario, Canada
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • McGill University Health Centre
    Montreal, Quebec, Canada
  • Hopital de la Timone
    Marseille, France
  • AP-HP Hopital Necker-Enfants Malades
    Paris, 75015, France
  • Universitatsklinikum Leipzig
    Leipzig, Saxony 04103, Germany
  • Universitatsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • The Edmond and Lily Safra Children's Hospital
    Ramat Gan, Israel
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, Barcelona, Spain
  • Hospital Universitari Parc Tauli
    Sabadell, Barcelona, Spain
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid, Spain
  • Cambridge University Hospitals
    Cambridge, United Kingdom
  • Great Ormond Street Hospital for Children
    London, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, OX3 7LE, United Kingdom
08

References and documents

Publications

  • Dindot SV, Christian S, Murphy WJ, Berent A, Panagoulias J, Schlafer A, Ballard J, Radeva K, Robinson R, Myers L, Jepp T, Shaheen H, Hillman P, Konganti K, Hillhouse A, Bredemeyer KR, Black L, Douville J; FIRE consortium; FIRE Consortium. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript. Sci Transl Med. 2023 Mar 22;15(688):eabf4077. doi: 10.1126/scitranslmed.abf4077. Epub 2023 Mar 22. PubMed 36947593 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jan 2025, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2020
First posted
Feb 6, 2020
StartActual
Feb 24, 2020
Primary completionActual
Jan 8, 2025
CompletionActual
Jan 8, 2025
Results delay requested
Jan 5, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04259281
Responsible party
Sponsor
First posted
Feb 6, 2020
Start date
Feb 24, 2020
Primary completion
Jan 8, 2025
Completion
Jan 8, 2025
Last update
Jan 9, 2026

Study contacts

Medical Director
study director · Ultragenyx Pharmaceutical Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apazunersen sodium

Start the discussion